Halozyme Therapeutics, Inc. (NASDAQ:HALO) Receives Average Recommendation of “Moderate Buy” from Brokerages

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has earned an average recommendation of “Moderate Buy” from the twelve analysts that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, four have given a hold rating and seven have issued a buy rating on the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is $80.6667.

Several research firms have issued reports on HALO. Wells Fargo & Company boosted their target price on Halozyme Therapeutics from $65.00 to $75.00 and gave the stock an “equal weight” rating in a research report on Thursday, February 19th. Morgan Stanley dropped their target price on Halozyme Therapeutics from $96.00 to $93.00 and set an “overweight” rating on the stock in a research report on Tuesday, May 12th. Benchmark boosted their target price on Halozyme Therapeutics from $75.00 to $90.00 and gave the stock a “buy” rating in a research report on Thursday, February 19th. TD Cowen reiterated a “buy” rating on shares of Halozyme Therapeutics in a research report on Wednesday, February 18th. Finally, HC Wainwright boosted their target price on Halozyme Therapeutics from $90.00 to $95.00 and gave the stock a “buy” rating in a research report on Wednesday, April 29th.

Halozyme Therapeutics Stock Performance

Shares of HALO stock opened at $68.65 on Thursday. The stock has a market capitalization of $8.14 billion, a PE ratio of 24.69, a price-to-earnings-growth ratio of 0.28 and a beta of 0.89. Halozyme Therapeutics has a 52-week low of $51.06 and a 52-week high of $82.22. The stock’s 50-day moving average price is $66.03 and its 200 day moving average price is $68.77. The company has a quick ratio of 2.33, a current ratio of 2.76 and a debt-to-equity ratio of 8.81.

Halozyme Therapeutics (NASDAQ:HALO) last issued its quarterly earnings results on Monday, May 11th. The biopharmaceutical company reported $1.60 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.06. The firm had revenue of $376.71 million for the quarter, compared to analysts’ expectations of $358.60 million. Halozyme Therapeutics had a return on equity of 187.91% and a net margin of 23.13%.The firm’s revenue for the quarter was up 42.2% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.11 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 7.750-8.250 EPS. As a group, equities research analysts forecast that Halozyme Therapeutics will post 7.65 EPS for the current year.

Insiders Place Their Bets

In other Halozyme Therapeutics news, COO Cortney Caudill sold 20,000 shares of the business’s stock in a transaction that occurred on Monday, March 9th. The stock was sold at an average price of $67.80, for a total transaction of $1,356,000.00. Following the transaction, the chief operating officer owned 14,366 shares in the company, valued at approximately $974,014.80. The trade was a 58.20% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, Director Bernadette Connaughton sold 1,625 shares of the business’s stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $63.48, for a total value of $103,155.00. Following the transaction, the director owned 38,498 shares in the company, valued at $2,443,853.04. The trade was a 4.05% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 120,482 shares of company stock worth $8,200,842. Company insiders own 2.50% of the company’s stock.

Institutional Investors Weigh In On Halozyme Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of HALO. DLD Asset Management LP grew its holdings in shares of Halozyme Therapeutics by 20.0% in the 3rd quarter. DLD Asset Management LP now owns 30,000,000 shares of the biopharmaceutical company’s stock worth $2,200,200,000 after acquiring an additional 5,000,000 shares during the period. Norges Bank acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter worth approximately $128,201,000. William Blair Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 4th quarter worth approximately $124,031,000. Federated Hermes Inc. grew its holdings in shares of Halozyme Therapeutics by 294.1% in the 3rd quarter. Federated Hermes Inc. now owns 1,450,704 shares of the biopharmaceutical company’s stock worth $106,395,000 after acquiring an additional 1,082,638 shares during the period. Finally, Voloridge Investment Management LLC acquired a new stake in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $77,587,000. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.